SAN DIEGO, APRIL 13, 2026 ― Jennifer Wargo, M.D., professor of Surgical Oncology and Genomic Medicine at The University of Texas MD Anderson Cancer Center, has been elected to the 2026 class of Fellows of the American Association for Cancer Research (AACR) Academy in recognition of her pioneering work to define interactions between the microbiome, cancer biology and treatment response. 

A team of Weill Cornell Medicine investigators is working to cross-train the next generation of cancer researchers in cancer biology and the use of artificial intelligence tools for research.

Recently, a significant study conducted collaboratively by multiple hospitals in Shanghai was published in the prestigious journal SCIENCE CHINA Life Sciences. This work uncovers for the first time that ovarian cancer drives tumor growth and metastasis by secreting IL-1β-enriched extracellular vesicles (EVs), which activate the NF-κB signaling pathway in adipose-derived stem cells (ADSCs), thereby inducing adipose tissue senescence and associated metabolic disorders. The team has identified two targeted intervention strategies: the senolytic combination of dasatinib and quercetin, or the natural NF-κB inhibitor resveratrol. Both approaches markedly eliminate senescent ADSCs, ameliorate metabolic abnormalities, and suppress ovarian cancer progression. This study provides novel insights into treating ovarian cancer by modulating the tumor microenvironment (TME) and targeting senescent cells, and underscores the translational potential of natural compounds including quercetin and resveratrol in clinical applications.